Nanotechnology

NEO Battery Materials Announces Appointment of Dr. Dongmok Whang as New Director

Retrieved on: 
Wednesday, April 3, 2024
NEO, Nanotechnology, Research, School, KBIA, Engineering, Samsung, OTC, LG Energy Solution, Ministry, Sungkyunkwan University, Silicon

Dr. Whang commented, “It is a great pleasure to be more deeply involved with the Company that is at the forefront of revolutionizing battery technology.

Key Points: 
  • Dr. Whang commented, “It is a great pleasure to be more deeply involved with the Company that is at the forefront of revolutionizing battery technology.
  • Only three years into R&D, NEO’s pace of performance optimization has been outstanding, considering that battery materials development is a tedious, taxing process.
  • NEO Battery Materials is pleased to announce that it has joined the Korea Battery Industry Association (“KBIA”).
  • Since its inception, the association supported the rise to prominence in the international battery market and organized the world’s leading battery conference, InterBattery.

Onto Innovation to Report First Quarter 2024 Financial Results on May 9, 2024

Retrieved on: 
Tuesday, April 9, 2024
Other Manufacturing, Technology, Semiconductor, Engineering, Nanotechnology, Manufacturing, Machinery, Electronic Design Automation, Consumer Electronics, Innovation

Onto Innovation Inc. (NYSE: ONTO) will release its 2024 first quarter results shortly after the market closes on May 9, 2024.

Key Points: 
  • Onto Innovation Inc. (NYSE: ONTO) will release its 2024 first quarter results shortly after the market closes on May 9, 2024.
  • Onto Innovation will host a conference call and audio webcast in connection with its release of the financial results.
  • Michael P. Plisinski, chief executive officer, and Mark Slicer, chief financial officer, will host the call.
  • To listen to the live webcast, please go to the website at least 15 minutes early to register, download and install any necessary audio software.

Frequency Launches Managed Channel Services to Support Rights Holders and Brands Creating Premium FAST Channels

Retrieved on: 
Tuesday, April 9, 2024
Satellite, Nanotechnology, Audio, Video, Other Technology, Telecommunications, TV and Radio, Software, Networks, Internet, Hardware, Electronic Design Automation, Data Management, Consumer Electronics, VoIP, Technology, Entertainment, Mobile, Wireless, General Entertainment, Warner Bros., MCS, FAST, Marketing, Vin Di Bona, Software as a service, Television, Video game

Frequency , the engine behind many of the world’s best-known streaming television channels, has launched a new Managed Channel Services (MCS) business unit that empowers rights holders, brands, talent and Free Ad-Supported Television (FAST) platforms to deploy premium streaming TV channels while accelerating time to market.

Key Points: 
  • Frequency , the engine behind many of the world’s best-known streaming television channels, has launched a new Managed Channel Services (MCS) business unit that empowers rights holders, brands, talent and Free Ad-Supported Television (FAST) platforms to deploy premium streaming TV channels while accelerating time to market.
  • Frequency has built a FAST and linear streaming team with expertise in all aspects of channel creation, including programming, operations and marketing.
  • Blair Harrison, founder and CEO of Frequency, says: “FAST content on leading platforms is moving from the sidelines to primetime.
  • The lines between FAST channels, traditional TV and subscription streaming services are becoming increasingly blurred, and ultimately viewers just want to watch great programming.

GlassHive Announces Collaboration with Microsoft to transform MSP Sales and Marketing to capture AI opportunity with customers

Retrieved on: 
Monday, April 8, 2024
Electronic Design Automation, Data Management, Consumer Electronics, Technology, VoIP, Mobile, Wireless, Semiconductor, Security, Small Business, Satellite, Other Professional Services, Photography, Nanotechnology, Audio, Video, Artificial Intelligence, Professional Services, Other Technology, Telecommunications, Software, Networks, Internet, Hardware, Cloud, Microsoft, GTM, Business, CRM, Automation, Partnership, Magic, AI, Marketing, Ingram Micro, Partner, Video game

This collaboration marks a significant initiative to empower Microsoft partners to effectively sell Microsoft Azure, Copilot for Microsoft 365, AI, Business Applications, and Business Intelligence Solutions to businesses worldwide.

Key Points: 
  • This collaboration marks a significant initiative to empower Microsoft partners to effectively sell Microsoft Azure, Copilot for Microsoft 365, AI, Business Applications, and Business Intelligence Solutions to businesses worldwide.
  • GlassHive, born and raised on Azure, utilizes AI to enhance partners' ability to market and sell services effectively.
  • Giovanni Sanguily, Founder and CEO of GlassHive, expressed his enthusiasm: "I'm thrilled to be working with Microsoft to empower the partner community.
  • Heather Deggans, VP of GTM for Microsoft Americas added, “Microsoft’s collaboration with GlassHive is a testament to our commitment to the partner ecosystem.

Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates

Retrieved on: 
Monday, April 8, 2024
Research, Technology, Semiconductor, Genetics, Health Technology, Nanotechnology, Biotechnology, Hardware, Health, Science, CNRS, CPMAS, 2000s, HCN, Membrane, Corporation, DNP, NMR, Bruker, Hertz, Protein, Multimedia, MAS, BRKR, WB, Medical imaging

Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.
  • Featuring a 160 kHz Magic Angle Spinning (MAS) system, it takes high-resolution MAS and proton detection on solid biological samples to the next level, enabling new scientific discoveries.
  • The dramatically enhanced 1H-NMR resolution and enhanced T2' times make 160 kHz MAS suitable for the study of large proteins, membrane proteins and protein aggregates.
  • In addition, a 160 kHz MAS probe is now installed on the 1.0 GHz NMR at CNRS Lyon, where it expands the scientific capabilities of biological solid-state research.

Aviceda Therapeutics Announces Formation of Renowned European Clinical Advisory Board

Retrieved on: 
Monday, April 8, 2024
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Faculty, Medical University of Vienna, Part, Patient, Queen's University, Optometry, Queen's University Belfast, CAB, MD, Royal Victoria Hospital, Laborie (company), Medical school, Therapy, Retina, Safety, AMD, Geographic atrophy, Pharmaceutical industry

Aviceda Therapeutics , a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today the formation of its European Clinical Advisory Board (CAB) made up of top internationally recognized thought leaders in retina to provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Key Points: 
  • Aviceda Therapeutics , a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today the formation of its European Clinical Advisory Board (CAB) made up of top internationally recognized thought leaders in retina to provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • The Company also announced that Tarek S. Hassan, MD will serve as Chair of the European and US CABs.
  • “We are excited that results from Part 1 of the US Phase 2/3 SIGLEC trial demonstrated functional and anatomic improvement in eyes with GA secondary to AMD after a single injection of AVD-104,” said Mohamed Genead, M.D., Aviceda’s Co-founder and CEO.
  • “With the contributions and support of this esteemed panel—and with Dr. Hassan as its chair—we look forward to bringing our clinical efforts to Europe later this year.”

Clinical Data Supports Novel Continuous Calprotectin Monitoring Wearable for IBD Management by EnLiSense

Retrieved on: 
Monday, April 8, 2024
Technology, Medical Devices, Health Technology, Nanotechnology, Other Health, Biotechnology, Hardware, Managed Care, Health, Data Management, Moses Austin, Conditional sentence, University, Professor, IL-6, Perspiration, Patient, Inflammation, Biomarker, Research, AI, Doctor of Philosophy, Senior, IBD, Translation, Management, C-reactive protein, Inflammatory bowel disease, Inflammatory Bowel Diseases, Trial of the century, CRP, Pharmaceutical industry

The study showcases the IBD Aware device's ability to non-invasively monitor calprotectin levels in both active and remission phases of IBD.

Key Points: 
  • The study showcases the IBD Aware device's ability to non-invasively monitor calprotectin levels in both active and remission phases of IBD.
  • These results not only affirm the accuracy of the IBD Aware device, but demonstrate its utility in the shifting paradigm of proactive IBD management that emphasizes continuous, data-driven decision-making.
  • “The IBD Aware device exemplifies our dedication to empowering healthcare professionals and enhancing patient outcomes through remote and continuous monitoring."
  • EnLiSense is pioneering work to build a future where proactive, personalized, and precision remote patient monitoring becomes the standard in chronic disease management.

Luna Innovations Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Retrieved on: 
Monday, April 8, 2024
Defense, Technology, Nanotechnology, Telecommunications, Software, Other Defense, Rule, Notice, Form, Form 10-K, Security (finance), Calendar, Cryptocurrency

This Notice has no immediate effect on the listing of the Company's shares on Nasdaq.

Key Points: 
  • This Notice has no immediate effect on the listing of the Company's shares on Nasdaq.
  • However, if the Company fails to timely regain compliance with the Rule, the Company's common stock will be subject to delisting from Nasdaq.
  • The Notice provides that the Company has 60 calendar days, or until June 30, 2024, to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule.
  • The Company is working diligently to complete its Form 10-K and will provide an update once more information is available.

IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington

Retrieved on: 
Tuesday, March 19, 2024
Brain, IBN, ALS, CNM, Patient, Mitochondrion, Nanotechnology, Interview

LOS ANGELES, March 19, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN , a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN) , recently appeared on First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials.

Key Points: 
  • LOS ANGELES, March 19, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN , a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN) , recently appeared on First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials.
  • During the interview, Etherington highlighted information about Clene’s work in the field of nanotechnology.
  • “For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood.
  • We then proceeded into two amyotrophic lateral sclerosis (ALS) studies and one multiple sclerosis study, all of which have concluded in the past 18 months.

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Retrieved on: 
Tuesday, March 12, 2024
CELU, Annual, Weill Cornell Medicine, Medical device, SBMT, Congress, Dementia, Innovation Park, Brain mapping, WBMF, Multiple sclerosis, Immunotherapy, Patient, Brain, Nanotechnology, Cancer, AI, Cell therapy, Society, Neurosurgery, Regenerative medicine, Therapy, DSM-IV codes, Cell, Virtual reality, Pharmaceutical industry

FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.

Key Points: 
  • FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.
  • Dr. Hariri’s keynote, titled, “Future of Cell and Immunotherapy – Cancer to Neurodegenerative Disorders,” will address cellular immunotherapy’s broad applications beyond cancer, including its potential use in neuroinflammatory and degenerative conditions, such as multiple sclerosis and Parkinson’s disease.
  • Celularity is advancing innovative cellular therapeutics to treat a range of diseases, including neurologic diseases from brain cancer to age-related cognitive decline.
  • SBMT’s 21st Annual World Congress will take place in Los Angeles, Calif., on March 14 through 17, 2024.